Does Semax help with post-stroke recovery?
Yes. Semax has significant clinical evidence in humans supporting its use for recovery after ischaemic stroke. This makes Semax the single best-established use in the entire published research base. Unlike many other uses discussed elsewhere, stroke recovery is an area where Semax actually has real clinical trial data behind it. It is not merely theoretical mechanisms or animal studies.
In a study of 110 patients following an ischaemic stroke – a stroke caused by a blocked blood vessel cutting off oxygen supply to part of the brain – Semax significantly increased plasma BDNF levels. This occurred regardless of when rehabilitation began. These elevated BDNF levels correlated directly with better scores on the Barthel Scale, a standard measure of a patient's ability to perform daily activities independently. They also correlated with a faster improvement in motor function [1]. This is actual human outcome data, not an extrapolation from animal models.
A previous clinical trial analysed 30 patients in the acute phase following a hemispheric ischaemic stroke. The researchers compared them with 80 control patients receiving only conventional therapy. The Semax group showed accelerated recovery of damaged neurological functions. Doses of 12 milligrams per day were considered most effective for moderate strokes, and 18 milligrams per day for severe ones. Treatment courses lasted 5–10 days [2]. This study also included objective monitoring — EEG mapping and somatosensory evoked potentials, measuring the speed of sensory signal processing by the brain. This confirmed that clinical improvements translated into measurable changes in brain function, not just subjective assessment [2].
Co mówią badania o tym, jak Semax pomaga w regeneracji po udarze?
Researchers have mapped in detail the mechanisms behind Semax's benefits in stroke at a molecular level. They used rat models with transiently blocked cerebral arteries, closely mimicking human ischemic stroke.
RNA sequencing analysis revealed something significant. Semax suppressed the activity of inflammation-related genes that stroke had pathologically activated. Simultaneously, it restored the activity of neurotransmission-related genes that stroke had suppressed [3]. This dual action—calming harmful post-stroke inflammation while simultaneously restoring normal brain signalling—appears in subsequent studies using different methods. One genome-wide analysis revealed that the immune response was the single most affected biological process under the influence of Semax treatment after stroke [4].
At the protein level, Semax increased active CREB. CREB is a protein central to the conversion of brain activity into lasting regeneration and memory processes. This increase occurred specifically in the stroke-damaged zone. Simultaneously, Semax reduced MMP-9, c-Fos, and active JNK – all markers associated with cell death and tissue damage in the surrounding brain tissue [5]. Semax also altered the activity of VEGF family genes, which control the formation and repair of blood vessels. These effects specifically counteracted the detrimental vascular disruption caused by the stroke itself [6].
In a clinical study of stroke patients, Semax shifted the balance of inflammatory markers towards an anti-inflammatory profile. It increased interleukin-10, while simultaneously reducing C-reactive protein, a marker of ongoing inflammation [7]. This directly connects the molecular mechanisms seen in animal studies with what is actually happening in human stroke patients.
Does Semax help with traumatic brain injury?
Direct evidence for Semax specifically in traumatic brain injury is more limited than for ischemic stroke. Related injury models, however, provide significant supporting data.
In one model, researchers induced a localised brain injury in the prefrontal cortex using a technique called photothrombosis. This injury bears some resemblance to focal traumatic brain injury. Chronic intranasal Semax completely restored spatial learning ability that had been impaired by the injury. This recovery persisted long after the treatment period had ended [8]. In a related model of experimental cortical injury, Semax reduced lesion volume and improved memory performance [9].
Research into spinal cord injury offers a different perspective. It is a different, yet mechanistically related, type of central nervous system injury. Semax induced significant functional regeneration here. It improved standardised scores of movement and coordination in injured animals. The mechanism involved reduced cell death and decreased oxidative stress [10].
These studies do not directly test Semax in the classical model of traumatic brain injury. However, the consistent pattern of neuroprotection and functional recovery across many injury types provides a reasonable basis for interest in TBI applications. Dedicated TBI studies have simply not yet been published.
Does Semax help with post-operative cognitive impairment or effects of anaesthesia?
No published research has directly tested Semax for post-operative cognitive impairment or recovery from anaesthesia. This is a genuine gap in current research.
However, the known mechanisms of Semax are relevant here. These include reducing inflammation, protecting against oxidative stress, and supporting the production of neurotrophic factors. All three processes are thought to underlie post-operative cognitive changes, increasingly linked to inflammatory and oxidative responses to surgery and anaesthesia. Until dedicated studies in this specific context are conducted, any use of Semax for cognitive support after anaesthesia remains speculative and unsupported by direct evidence.
What is the general clinical picture for Semax and stroke?
Semax stands out in the broader literature on Semax. Stroke and cerebrovascular disease represent areas with the most significant, most consistent, and most clinically relevant human evidence available.
In addition to the studies already discussed, a clinical trial involving 187 patients with cerebrovascular insufficiency—a condition that involves chronically reduced blood flow to the brain—showed significant results. Treatment with Semax brought about significant clinical improvement. It stabilised the progression of the disease. It reduced the risk of subsequent strokes and transient ischaemic attacks. And it demonstrated good tolerability even in elderly patients [11].
This body of evidence encompasses acute stroke treatment, rehabilitation, and prevention of further cerebrovascular events. It represents the strongest and most clinically translated application of Semax currently documented in the scientific literature.
Does Semax help with Alzheimer's disease?
Evidence for Semax in Alzheimer's disease is promising but remains entirely preclinical. To date, no clinical human trials have been conducted in Alzheimer's patients.
The most direct evidence comes from a 2025 study using transgenic mice – mice genetically engineered to develop amyloid plaques similar to those seen in human Alzheimer's disease. In this model, both Semax and the peptide derivative improved cognitive function. This was demonstrated in multiple behavioural tests, including the open field, novel object recognition, and Barnes maze. Microscopic examination of brain tissue revealed that both peptides reduced the number of amyloid plaque deposits in the cortex and hippocampus [12].
A separate line of research investigated the direct chemical interaction of Semax with beta-amyloid, the protein that forms Alzheimer's plaques. Semax inhibited copper-induced beta-amyloid aggregation. It interfered with the formation of toxic amyloid fibrils in artificial membrane models [13]. Copper plays a significant role in Alzheimer's pathology. It catalyzes harmful oxidative reactions when bound to beta-amyloid. Semax was found to extract copper from these toxic copper-amyloid complexes. This reduced the harmful free radical production that this copper-amyloid interaction normally generates. Semax also demonstrated protective effects against copper-induced cell death in laboratory nerve cells [14].
Does Semax help with dementia more broadly?
Beyond amyloid-specific mechanisms relevant to Alzheimer's, Semax's broader neuroprotective profile is mechanistically relevant for dementia generally. This includes elevated BDNF and NGF, protection of cholinergic neurons – the acetylcholine-producing nerve cells crucial for memory – and antioxidant activity. These are some of the biological systems most consistently disrupted across various forms of cognitive decline.
Semax increased the survival of cholinergic neurons from the basal forebrain by 1.5 to 1.7 times in cell culture. It also stimulated the activity of choline acetyltransferase, the enzyme responsible for the production of acetylcholine [15]. This is particularly important. The cholinergic neurons of the basal forebrain are among the earliest and most severely affected cell populations in Alzheimer's disease. Their loss is closely linked to the memory impairment that characterises this condition.
Does Semax help with Parkinson's disease?
Semax has demonstrated neuroprotective effects in multiple animal models specifically designed to mimic Parkinson's disease. Parkinson's focuses on the loss of dopamine-producing neurons in a brain area called the substantia nigra.
Researchers commonly use the neurotoxin MPTP to induce Parkinson's-like dopaminergic damage in animals. In this model, daily intranasal Semax reduced the severity of neurotoxin-induced behavioural impairments. This included reduced movement and increased anxiety, both typical in this model [16]. A more recent study used an improved mouse model that specifically tracks the degeneration of dopamine-producing nerve fibres. Semax administered before MPTP treatment caused a small but statistically significant increase in striatal dopamine levels. Researchers concluded that Semax acts primarily by stimulating the brain's own production of neurotrophic factors rather than mainly as a direct antioxidant [17].
A separate study looked at Semax and Selank together in rats with chemically induced Parkinson's disease. Neither peptide significantly affected the animals' motor activity. However, Selank did reduce anxiety levels in these Parkinsonian rats. This effect had previously only been seen in healthy animals [18]. This finding suggests something interesting. The nigrostriatal damage characteristic of Parkinson's disease does not eliminate the brain's reactivity to these peptides' effects on emotional behaviour – even though neither peptide reversed the main motor symptoms in this particular study.
Can Semax slow the decline in cognitive function?
Based on available mechanisms and evidence from animal models, Semax has a plausible potential to support cognitive function and slow certain aspects of cognitive decline. However, this has not been directly tested in humans experiencing age-related cognitive decline or diagnosed neurodegenerative diseases.
A consistent thread runs through animal studies concerning Alzheimer's and Parkinson's. Increase in BDNF and NGF. Antioxidant protection. Reduction of neuroinflammation. Support for vulnerable neuronal populations, such as the cholinergic cells of the basal forebrain and the dopaminergic cells of the substantia nigra. Together, these support the biological plausibility of Semax as a cognitive decline-slowing agent.
Being biologically plausible based on animal models is, however, significantly different from being clinically proven to slow cognitive decline in humans. No study has yet bridged this gap.
What is the full evidence base for Semax neuroprotection?
The neuroprotective profile of Semax is supported by an extremely broad and mechanistically diverse body of research. This includes ischaemic stroke, spinal cord injury, focal cortical injury, Parkinson’s models, Alzheimer’s models, glutamate excitotoxicity, and oxidative stress across multiple cell types and injury paradigms.
This breadth is truly noteworthy. Few research compounds have been tested across so many distinct injury models with such mechanistic consistency of outcomes. The hierarchy of evidence assigns the strongest trust to findings related to ischemic stroke, incorporating real-world data from human clinical trials [1], [2], [7], [11]. Findings related to Alzheimer's, Parkinson's, and spinal cord injury remain at the animal study phase.
Semax's key neuroprotective mechanisms include its effect on brain-derived neurotrophic factor (BDNF) and its antioxidant properties. It also influences nitric oxide (NO) production and signalling pathways.
Semax protects neurons through several interconnected mechanisms working together, rather than through a single pathway.
The most consistently documented mechanism is the increase in neurotrophic factors. Increases in BDNF and NGF support neuron survival, growth, and the resilience of neuronal circuits under stress [19]. The second major mechanism is the anti-inflammatory regulation of genes. Whole-genome RNA sequencing studies show that Semax suppresses the activity of inflammatory genes activated by brain injury, while restoring the activity of genes necessary for normal neural signalling [3], [4].
The third mechanism is antioxidant activity. This manifests itself in several ways. Semax prevents the excessive production of nitric oxide and lipid peroxidation after cerebral ischemia [20]. It directly chelates – binds and removes – copper ions which would otherwise catalyse harmful oxidative reactions [14]. And it protects cells exposed to oxidative stress induced by hydrogen peroxide [21].
The fourth mechanism involves calcium and mitochondrial protection. Semax delayed the calcium overload and mitochondrial dysfunction that occur during glutamate-induced excitotoxicity — a type of nerve cell damage caused by excessive stimulation. This improved neuronal survival by approximately 30% in cultured cerebellar cells under this type of toxic stress [22].
The fifth mechanism concerns vascular support. Semax modulates the expression of VEGF family genes [6], which control blood vessel formation. It also improves erythrocyte deformability – the ability of red blood cells to squeeze through narrow vessels – which enhances blood flow through the narrow capillaries of the brain [23].
Finally, a newly identified mechanism pertains to the μ-opioid receptor pathway. Spinal cord injury research has revealed that Semax promotes a cellular process called deubiquitination. This stabilises lysosomal membranes and reduces a specific form of inflammatory cell death known as pyroptosis [10]. This adds a newly discovered molecular mechanism to an already significant list.
What do studies show about Semax and oxidative stress specifically?
Evidence of oxidative stress for Semax includes several distinct experimental approaches. All of them consistently point in the same protective direction.
In models of global cerebral ischaemia, Semax prevented an approximately twofold increase in nitric oxide production that typically occurs following this type of injury. Glycine, tested in the same study for comparison, showed no such protective effect [20]. This is an important finding. It demonstrates specificity. Semax's antioxidant action is not simply a general characteristic shared by every neuroactive compound. It appears to reflect a true pharmacological property of this particular peptide.
In cell culture studies, Semax dose-dependently protected cultured cells from death caused by exposure to hydrogen peroxide. The degree of protection depended on the timing of peptide introduction relative to the oxidative stimulus [21]. In behavioural studies, Semax counteracted learning and memory impairment induced by exposure to heavy metals—specifically lead and molybdenum. It was as effective as ascorbic acid, a well-established antioxidant [24]. This provides indirect behavioural confirmation of antioxidant activity in a live animal.
What does research show about Semax and neuroinflammation specifically?
Evidence for neuroinflammation is arguably the most accurately characterised aspect of Semax's neuroprotective profile. It is based on numerous genome-wide studies conducted by the same Russian research groups over more than a decade.
The earliest of these studies revealed something striking. Over half of all genes affected by Semax in the rat post-stroke brain were immune response genes. Particularly notable effects were seen on genes encoding immunoglobulins and chemokines—both types of immune signalling molecules [4]. A control study using precise gene measurement techniques confirmed that Semax induced statistically significant reductions in specific pro-inflammatory signalling proteins. These included IL-1α, IL-1β, IL-6, CCL3, and CXCL2 in the ischaemic rat brain [25].
More recent RNA sequencing studies have extended these findings to earlier time points after stroke. They demonstrated that Semax and a related peptide can partially prevent disturbances in genes associated with inflammation and neurosignalling as early as 4.5 hours after an ischaemic event [26]. This timing is clinically relevant. It falls within the therapeutic window where stroke treatment is typically most effective.
How does Semax compare with other neuroprotective compounds?
In available comparative studies, Semax has been tested alongside several other neuroprotective factors. The results differ depending on the measured indicator.
In direct comparison with mexidol, a well-established Russian neuroprotective drug, both compounds demonstrated anti-hypoxic and anti-amnestic effects in models of cerebral ischaemia. However, they followed different dose-response patterns. Mexidol exhibited a linear dose-effect relationship. Semax, instead, followed a bell-shaped curve – efficacy increased and then decreased at higher doses [27].
In a comparison analysing PGC-1α—a key regulator of brain resistance to ischemic damage—both mexidol and Semax preserved neuronal counts and PGC-1α activity in the tissue surrounding photochemically induced brain injury. This suggests a roughly comparable neuroprotective strength between the two compounds in this specific model [28].
Compared to the new tripeptide mixture tested in one study, Semax actually performed worse in several measures. These included anti-hypoxic and anti-amnestic effects. The new mixture showed 1.3 to 4 times greater efficacy, depending on the specific test [29]. This is a useful reminder. Semax, while extensively studied, is not necessarily the most potent neuroprotective compound available - even within the narrow category of Russian-developed peptides and small-molecule neuroprotectors.
What are the limitations of current research into the neuroprotection of Semax?
A few significant limitations should temper enthusiasm for Semax's neuroprotective profile. This is true even given a truly significant body of supporting evidence.
First and foremost, the vast majority of these studies originate from a relatively small number of Russian research institutions. Independent replication by research groups outside of this network is limited. This is a significant consideration for scientific certainty, regardless of how internally consistent the results may appear.
Secondly, whilst the stroke has real clinical trial data, the sample sizes – ranging from 30 to 187 patients in available studies – are small by modern clinical trial standards. None of the published human studies employed a double-blind, placebo-controlled, large-scale design that would be required for regulatory approval in most Western countries.
Thirdly, applications in Alzheimer's, Parkinson's and traumatic brain injury remain entirely at the animal research stage. No human trials have been conducted for these specific conditions.
Fourth, most mechanistic studies use young, healthy animals, not older animals with comorbidities. Real-life human patients experiencing these neurodegenerative diseases in clinical practice more closely resemble the latter group.
Addressing these limitations through modern, rigorously controlled human studies would significantly strengthen the arguments for Semax's neuroprotective applications. It would also help clarify precisely which patient populations and conditions are most likely to benefit.
Disclaimer
This content is for educational and informational-scientific purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Semax remains a research compound in most countries, including the United States and most European countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries. The strongest evidence in humans pertains specifically to ischaemic stroke and cerebrovascular disease. Evidence for Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury remains entirely preclinical, with no published human studies in these specific conditions. Additional, well-designed, large-scale clinical trials are necessary to confirm these preclinical findings in humans. Any individual with a neurological condition should consult a qualified healthcare professional and should not alter, discontinue, or substitute any prescribed treatment without medical guidance.
References
1. Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[2] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[3] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[4] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischaemia: Genome-wide transcriptional analysis. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[5] Sudarkina, O. Yu., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischaemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[6] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2013). Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischaemia of the rat brain. Journal of Molecular Neuroscience, 49(2), 328–333. https://doi.org/10.1007/s12031-012-9853-y
[7] Miasoedova, N. F., Skvortsova, V. I., Nasonov, E. L., Zhuravleva, E. Yu., Grivennikov, I. A., Arsen’eva, E. L., & Sukhanov, I. I. (1999). Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 99(5), 15–19. PMID: 10358912
[8] Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischaemic lesions to the prefrontal cortex. Neuroscience and Behavioral Physiology, 39(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
Romanova, G. A., Silachev, D. N., Shakova, F. M., Kvashennikova, Yu. N., Viktorov, I. V., Shram, S. I., & Myasoedov, N. F. (2006). Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine, 142(6), 663-666. https://doi.org/10.1007/s10517-006-0445-0
[10] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[11] Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[12] Radchenko, A. I., Kuzubova, E. V., Apostol, A. A., Mitkevich, V. A., Andreeva, L. A., Limborskaya, S. A., Stepenko, Yu. V., Shmigerova, V. S., Solin, A. V., Korokin, M. V., Pokrovskiy, M. V., Myasoedov, N. F., & Makarov, A. A. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 17(4), 110–120. https://doi.org/10.32607/actanaturae.27808
[13] Sciacca, M. F. M., Naletova, I., Giuffrida, M. L., & Attanasio, F. (2022). Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience, 13(4), 486–496. https://doi.org/10.1021/acschemneuro.1c00707
[14] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalysed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[15] Grivennikov, I. A., Dolotov, O. V., Zolotarev, Yu. A., Andreeva, L. A., Myasoedov, N. F., Leacher, L., Black, I. B., & Dreyfus, C. F. (2008). Effects of behaviourally active ACTH(4-10) analogue — Semax on rat basal forebrain cholinergic neurons. Restorative Neurology and Neuroscience, 26(1), 35–43. PMID: 18431004
[16] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioural Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
[17] Kolacheva, A. A., & Ugrumov, M. V. (2021). A mouse model of nigrostriatal dopaminergic axonal degeneration as a tool for testing neuroprotectors. Acta Naturae, 13(3), 110–113. https://doi.org/10.32607/actanaturae.11433
Slominsky, P. A., Shadrina, M. I., Kolomin, T. A., Stavrovskaya, A. V., Filatova, E. V., Andreeva, L. A., Illarioshkin, S. N., & Myasoedov, N. F. (2017). Peptides semax and selank affect the behaviour of rats with 6-OHDA induced PD-like parkinsonism. Doklady Biological Sciences, 474(1), 106-109. https://doi.org/10.1134/S0012496617030048
[19] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[20] Bashkatova, V. G., Koshelev, V. B., Fadyukova, O. E., Alexeev, A. A., Vanin, A. F., Rayevsky, K. S., Ashmarin, I. P., & Armstrong, D. M. (2001). Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischaemia. Brain Research, 894(1), 145–149. https://doi.org/10.1016/s0006-8993(00)03324-2
[21] Safarova, E. R., Shram, S. I., Zolotarev, Yu. A., & Myasoedov, N. F. (2003). Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress. Bulletin of Experimental Biology and Medicine, 135(3), 268–271. https://doi.org/10.1023/a:1024141232307
[22] Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
[23] Fadyukova, O. E., Tyurina, A. Yu., Lugovtsov, A. E., Priezzhev, A. V., Andreeva, L. A., Koshelev, V. B., & Myasoedov, N. F. (2011). Semax increases erythrocyte deformability in the shearing blood stream in intact rats and rats with cerebral ischaemia. Doklady Biological Sciences, 439, 208–211. https://doi.org/10.1134/S0012496611040168
[24] Inozemtsev, A. N., Bokieva, S. B., Karpukhina, O. V., Gumargalieva, K. Z., Kamensky, A. A., & Myasoedov, N. F. (2016). Semax prevents learning and memory inhibition by heavy metals. Doklady Biological Sciences, 468(1), 112–114. https://doi.org/10.1134/S0012496616030066
[25] Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischaemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[26] Filippenkov, I. B., Remizova, J. A., Stavchansky, V. V., Denisova, A. E., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2023). Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes, 14(7), 1382. https://doi.org/10.3390/genes14071382
Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of mexidol and semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550
[28] Shakova, F. M., Kirova, Yu. I., Silachev, D. N., Romanova, G. A., & Morozov, S. G. (2021). Protective effects of PGC-1α activators on ischaemic stroke in a rat model of photochemically induced thrombosis. Brain Sciences, 11(3), 325. https://doi.org/10.3390/brainsci11030325
[29] Iasnetsov, V. V., Chertorizhskiĭ, E. A., Belyĭ, P. A., Bespalova, Zh. D., Ovchinnikov, M. V., Vereshchagina, A. O., Ivanov, Yu. V., Iasnetsov, Vik. V., Kirsanova, S. K., & Motin, V. G. (2015). Study of neuroprotective, antihypoxic and antiamnesic effects of a new mixture of tripeptides. Experimental and Clinical Pharmacology, 78(1), 3–8. PMID: 25826866